- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05268575
A Study on the Endoscopic Treatments of Hemorrhoids
Comparative Study on Endoscopic Treatments for Hemorrhoids (METHOD): a Multicenter, Randomized Controlled Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In this trial, investigators plan to conduct a multicenter, randomized controlled clinical trial. The leader of the sponsoring organization strictly implements oversight of the protocol. Investigators intend to compare the total efficiency of the endoscopic sclerotherapy group, the endoscopic rubber band ligation group, and the endoscopic sclerotherapy combined with rubber band ligation group for the treatment of hemorrhoids. The Department of Gastroenterology at Jinling Hospital will take full charge of this trial, including recruitment of patients, endoscopic treatment, in-hospital nursing, follow-up work, etc. Informed consent forms from every patient will be signed before enrollment, and approval from the Ethical Committees of Jinling Hospital has been obtained.
After patients will be admitted to the hospital and sign informed consent, they will be randomly assigned to the endoscopic sclerotherapy group, the endoscopic rubber band ligation group, and the endoscopic sclerotherapy combined with rubber band ligation group in a 1:1:1 ratio of 130 patients in each group, and the assignment will be done by a mobile client randomization tool. Patients in each group completed bowel preparation according to the same requirements and performed the appropriate endoscopic treatment. The sclerosing agent is polydocanol and the ligature model is MBL-6-F.
Our main observation is the overall effectiveness rate (the ratio of the number of people whose symptoms improved and the number of people whose symptoms completely disappeared to the total number of people). Our secondary observation indicators are the incidence of complications (such as urinary retention, prostatic abscess, fecal incontinence, rectal stricture, infection, bacteraemia, etc.) within 1 year after hemorrhoid treatment, the presence of new symptoms within 1 year after treatment, the recurrence rate after treatment, patient satisfaction, endoscopic performance of hemorrhoids, intraoperative conditions, hospital days, hospital costs, the need for retreatment due to recurrence or worsening of symptoms, blood routine, urine routine, fecal routine, coagulation function, blood biochemistry, etc.
Investigators will observe the status of patients 48 hours after treatment, 3 month after treatment, 6 months after treatment, 9 months after treatment, and 1 year after treatment. Follow-up will be conducted through online questionnaires or telephone callbacks.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Fangyu Wang
- Phone Number: +8613515100636
- Email: wangfy65@nju.edu.cn
Study Contact Backup
- Name: Zhihao Ding
- Phone Number: +8615061586037
- Email: d382428060@163.com
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210002
- Jinling Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Sign a written informed consent form.
- Age 18-80 years with clinical symptoms of hemorrhoids.
- Subjects able to follow the follow-up schedule, able to describe symptoms objectively and able to cooperate in completing the scale.
- non-breastfeeding pregnant women and those with no pregnancy planned during the trial
- not participating in various clinical trials in the 3 months prior to and during the trial
- Not taking long-term anticoagulant drugs (e.g., clopidogrel, aspirin, triptans, etc.) or have stopped taking them for 5-7 days.
Exclusion Criteria:
- those with severe organ insufficiency of the heart, brain, lungs and kidneys
- those who cannot tolerate endoscopic treatment
- those with severe coagulation disorders
- men with a history of severe prostate enlargement
- with severe intestinal diseases: colon malignancy, ulcerative colitis, Crohn's disease, anal fistula, anal fissure, acute thrombosed internal hemorrhoids
- those who are allergic to sclerosing agents
- Those who, in the opinion of the investigator, cannot be enrolled for any reason.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: endoscopic sclerotherapy
Patients with hemorrhoids will be treated with endoscopic sclerotherapy.
Injection site is submucosa of hemorrhoid nucleus.
Sclerosing agent makes the submucosal tissue fibrotic, and then fixes the hemorrhoidal tissue.
|
Hemorrhoids will be treated by endoscopic sclerotherapy or endoscopic rubber band ligation or endoscopic sclerotherapy combined with rubber band ligation
Other Names:
|
Experimental: endoscopic rubber band ligation
Patients with hemorrhoids will be treated with endoscopic rubber band ligation.
The ligature position is above the mucosa of the hemorrhoid nucleus.
Ligation of hemorrhoidal tissue can lead to ischemic necrosis of the prolapsed mucosa, which in turn leads to scar fixation.
At the same time, the ligature also has the effect of lifting the tissue upward.
|
Hemorrhoids will be treated by endoscopic sclerotherapy or endoscopic rubber band ligation or endoscopic sclerotherapy combined with rubber band ligation
Other Names:
|
Experimental: endoscopic sclerotherapy combined with rubber band ligation
Patients with hemorrhoids will be treated with endoscopic sclerotherapy combined with rubber band ligation.
Sclerotherapy first, followed by rubber band ligation.
Sclerotherapy injection reduces the likelihood of ligature dislodgement.
|
Hemorrhoids will be treated by endoscopic sclerotherapy or endoscopic rubber band ligation or endoscopic sclerotherapy combined with rubber band ligation
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total effective rate
Time Frame: one year
|
Total effective rate includes effective rate and cure rate.
Effective rate means that symptoms are better than before treatment;Cure rate refers to the percentage of symptoms that completely disappear.
|
one year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of complications
Time Frame: 1 year
|
Incidence of complications such as urinary retention, anal stricture, etc. within 1 year
|
1 year
|
Incidence of new symptoms
Time Frame: 1 year
|
Incidence of new symptoms such as bleeding, pain, etc. within 1 year
|
1 year
|
Recurrence rate after treatment
Time Frame: 1 year
|
Recurrence rate after 1 year of treatment
|
1 year
|
Patient satisfaction
Time Frame: 1 year
|
A questionnaire was used to obtain patients' responses regarding their satisfaction with the treatment, with the following three options: satisfied, indifferent, and dissatisfied.
|
1 year
|
Endoscopic presentation of hemorrhoids
Time Frame: 1 year
|
Circumferential distribution of hemorrhoids, the diameter of the largest hemorrhoids, presence of red color signs (change in the color of the surface of the rectal column in accordance with the general rules for endoscopic findings of esophagogastric varices)
|
1 year
|
Intraoperative situation
Time Frame: 1 year
|
The amount of intraoperative bleeding and whether the patient had discomfort during the operation.
|
1 year
|
Number of days in hospital
Time Frame: 1 year
|
Number of days in hospital
|
1 year
|
Hospitalization Costs
Time Frame: 1 year
|
Hospitalization Costs
|
1 year
|
Incidence of needing re-treatment
Time Frame: 1 year
|
Need for retreatment due to recurrence or worsening of symptoms
|
1 year
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Yamana T. Japanese Practice Guidelines for Anal Disorders I. Hemorrhoids. J Anus Rectum Colon. 2018 May 25;1(3):89-99. doi: 10.23922/jarc.2017-018. eCollection 2017.
- Madoff RD, Fleshman JW; Clinical Practice Committee, American Gastroenterological Association. American Gastroenterological Association technical review on the diagnosis and treatment of hemorrhoids. Gastroenterology. 2004 May;126(5):1463-73. doi: 10.1053/j.gastro.2004.03.008. No abstract available.
- Ma W, Guo J, Yang F, Dietrich CF, Sun S. Progress in Endoscopic Treatment of Hemorrhoids. J Transl Int Med. 2020 Dec 31;8(4):237-244. doi: 10.2478/jtim-2020-0036. eCollection 2020 Dec.
- Davis BR, Lee-Kong SA, Migaly J, Feingold DL, Steele SR. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Hemorrhoids. Dis Colon Rectum. 2018 Mar;61(3):284-292. doi: 10.1097/DCR.0000000000001030. No abstract available.
- Awad AE, Soliman HH, Saif SA, Darwish AM, Mosaad S, Elfert AA. A prospective randomised comparative study of endoscopic band ligation versus injection sclerotherapy of bleeding internal haemorrhoids in patients with liver cirrhosis. Arab J Gastroenterol. 2012 Jun;13(2):77-81. doi: 10.1016/j.ajg.2012.03.008. Epub 2012 Apr 24.
- Kanellos I, Goulimaris I, Christoforidis E, Kelpis T, Betsis D. A comparison of the simultaneous application of sclerotherapy and rubber band ligation, with sclerotherapy and rubber band ligation applied separately, for the treatment of haemorrhoids: a prospective randomized trial. Colorectal Dis. 2003 Mar;5(2):133-8. doi: 10.1046/j.1463-1318.2003.00395.x.
- Abiodun AA, Alatise OI, Okereke CE, Adesunkanmi AK, Eletta EA, Gomna A. Comparative study of endoscopic band ligation versus injection sclerotherapy with 50% dextrose in water, in symptomatic internal haemorrhoids. Niger Postgrad Med J. 2020 Jan-Mar;27(1):13-20. doi: 10.4103/npmj.npmj_128_19.
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DZQH-KYLLSL-21-15
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemorrhoids
-
Vilnius UniversityBiolitec Pharma Ltd.UnknownHemorrhoids Second Degree | Hemorrhoids Third DegreeLithuania
-
Ventrus Biosciences, IncTerminatedInternal HemorrhoidsUnited States
-
Societa Italiana di Chirurgia ColoRettaleSICCR - Gaetano GalloCompletedSecond-degree HemorrhoidsItaly
-
Medtronic - MITGCompletedHemorrhoids, InternalUnited States
-
The Second Affiliated Hospital of Hunan University...Hunan University of Traditional Chinese Medicine; Zhengfeng Medical Technology...Unknown
-
Universitätsklinikum Hamburg-EppendorfCompletedInternal Hemorrhoids
-
BayerCompletedAcute HemorrhoidsRussian Federation
-
Nivagen Pharmaceuticals Inc.CompletedInternal HemorrhoidsUnited States, India
-
Universidade do PortoCompletedHemorrhoids, InternalPortugal
-
G & W Laboratories Inc.CompletedInternal HemorrhoidsUnited States
Clinical Trials on performing endoscopy
-
Nantes University HospitalCompleted
-
Bait Balev HospitalCompletedLow Back Pain | OsteoporosisIsrael
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
Centre Hospitalier Universitaire de Saint EtienneTerminatedQuality of Life | Exercise | Healthy Volunteers | HealthFrance
-
Assistance Publique Hopitaux De MarseilleTerminatedPregnant Women Suspected of COVID-19France
-
Southern HealthJohnson & JohnsonUnknownVaginal HysterectomyAustralia
-
Assaf-Harofeh Medical CenterMeir Medical Center; Nazareth HospitalRecruiting
-
AdventHealthDr. Phillips Center for the Performing ArtsCompleted
-
Jordan Collaborating Cardiology GroupRecruiting